2FIRSTS and IEVA Announce Strategic Partnership for E-cigarette Market

Jan.17.2023
2FIRSTS and IEVA Announce Strategic Partnership for E-cigarette Market
2FIRSTS and IEVA announce strategic cooperation to advance the development of China's electronic cigarette supply chain and European market.

Ieva partners with 2Firsts for a strategic collaboration.


Recently, 2FIRSTS and the Independent European Vaping Alliance (IEVA) jointly announced a strategic partnership to promote the coordinated development of the Chinese electronic cigarette supply chain and the European electronic cigarette consumer market. The IEVA is one of the most influential electronic cigarette association organizations in the world and is deeply involved in the formulation of electronic cigarette policies in the European Union. 2FIRSTS is a globally influential vaporization technology media and think tank institution that has already launched websites in Chinese (2firsts.cn), English (2firsts.com), and Russian (2firsts.ru), covering industry practitioners worldwide.


2FIRSTS has announced a strategic partnership with IEVA to focus on areas such as member services, EU regulatory policies, market access, and environmental protection. Europe is one of the most important markets for e-cigarettes worldwide and serves as an industry trendsetter, with its regulatory policies, popular product categories, and market state having a significant global impact. The partnership between 2FIRSTS and IEVA aims to further promote compliance and healthy development of the e-cigarette market in Europe and enhance the level of internationalization in the Chinese e-cigarette supply chain, contributing to the prosperity of e-cigarette trade between China and the EU.


Two companies, 2FIRSTS and IEVA, met in London, UK. Image source: 2FIRSTS.


2FIRSTS has been invited to participate in the IEVA 2022 Brussels Conference. Image source: 2FIRSTS.


The Functions of IEVA China Member Office


As a significant aspect of the strategic collaboration between 2FIRSTS and IEVA, the IEVA China member office will be established in Shenzhen with operational responsibilities handled by 2FIRSTS.


With the media influence and professional expertise of 2FIRSTS, the IEVA China member office will provide the following value:


Policy Promotion: Timely communicate the updates on EU regulations and taxes on electronic cigarettes to Chinese manufacturers to assist them in complying with regulations. Membership Website: A special section for IEVA members will be developed on the 2FIRSTS website to keep members informed on latest updates, EU regulations and market trends. Member Activities: IEVA and 2FIRSTS will organize events such as exchange salons, industry summits, and closed-door member training sessions to further enhance their value-added services to Chinese members. Membership Recruitment: IEVA and 2FIRSTS will jointly design a membership system that is better suited for the Chinese market and enhance their ability to serve businesses of different sizes.


After the Chinese New Year, the "EU Market Week" event will begin.


After the Chinese New Year in 2023, 2FIRSTS and IEVA will be collaborating to launch the "EU Market Week" event. The event will feature policy presentations, live market information broadcasts, offline activities, and more, all aimed at enhancing Chinese businesses' understanding of the EU market. Following their successful "Russian Market Week" event in January, this is another major initiative from 2FIRSTS to kick off the year. Fostering sustainable international market communication and promoting international cooperation will contribute greatly to the high-quality overseas expansion and healthy growth of the Chinese e-cigarette industry in 2023.


Contact information for the IEVA China Membership Office:


Address: Unit 1605, Tower A, Yifang Center, Xin'an Street, Bao'an District, Shenzhen City, Guangdong Province.


Contact person: Jason


Email address: IEVA.China@2firsts.com



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | Philip Morris Japan Launches Ginza-Exclusive IQOS ILUMA i PRIME, Limited to 1,814 Units at First Global Flagship
Product | Philip Morris Japan Launches Ginza-Exclusive IQOS ILUMA i PRIME, Limited to 1,814 Units at First Global Flagship
Philip Morris Japan (PMJ) launched the IQOS ILUMA i PRIME Ginza Limited Model Set in Tokyo on September 4, 2026, alongside the opening of IQOS Flagship Ginza, the brand’s first global flagship store. The Oasis Blue edition is limited to 1,814 individually numbered units, with the figure derived from the store’s address at Ginza 1-8-14. The set also includes two Yamanaka-nuri glasses and special packaging, priced at JPY 11,980 and sold exclusively at the Ginza flagship.
Sep.07
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30
From Product Innovation to Integrated Solutions: NEXTECH Expands Its Global Heated Tobacco Solutions
From Product Innovation to Integrated Solutions: NEXTECH Expands Its Global Heated Tobacco Solutions
NEXTECH launched its NEXE Pro circumferential-heating tobacco stick globally at InterTabac 2026, as the company expands from product innovation into broader heated tobacco solutions. Amid intensifying competition across global HTP markets, NEXTECH is strengthening its R&D, manufacturing and pre-launch support capabilities to serve different types of business customers.
Industry Insight
Sep.15